• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对涉及建模与仿真的项目所提议的最佳实践方法。

Proposed best practice for projects that involve modelling and simulation.

作者信息

O'Kelly Michael, Anisimov Vladimir, Campbell Chris, Hamilton Sinéad

机构信息

Quintiles, Dublin, Ireland.

University of Glasgow, Glasgow, Scotland.

出版信息

Pharm Stat. 2017 Mar;16(2):107-113. doi: 10.1002/pst.1789. Epub 2016 Nov 3.

DOI:10.1002/pst.1789
PMID:27809406
Abstract

Modelling and simulation has been used in many ways when developing new treatments. To be useful and credible, it is generally agreed that modelling and simulation should be undertaken according to some kind of best practice. A number of authors have suggested elements required for best practice in modelling and simulation. Elements that have been suggested include the pre-specification of goals, assumptions, methods, and outputs. However, a project that involves modelling and simulation could be simple or complex and could be of relatively low or high importance to the project. It has been argued that the level of detail and the strictness of pre-specification should be allowed to vary, depending on the complexity and importance of the project. This best practice document does not prescribe how to develop a statistical model. Rather, it describes the elements required for the specification of a project and requires that the practitioner justify in the specification the omission of any of the elements and, in addition, justify the level of detail provided about each element. This document is an initiative of the Special Interest Group for modelling and simulation. The Special Interest Group for modelling and simulation is a body open to members of Statisticians in the Pharmaceutical Industry and the European Federation of Statisticians in the Pharmaceutical Industry. Examples of a very detailed specification and a less detailed specification are included as appendices.

摘要

在开发新疗法时,建模与模拟已被广泛应用于多种方式。为了有用且可信,人们普遍认为建模与模拟应按照某种最佳实践来进行。许多作者提出了建模与模拟最佳实践所需的要素。已被提出的要素包括目标、假设、方法和输出的预先设定。然而,一个涉及建模与模拟的项目可能简单或复杂,并且对该项目的重要性可能相对较低或较高。有人认为,应根据项目的复杂性和重要性,允许细节程度和预先设定的严格程度有所不同。本最佳实践文件并未规定如何开发统计模型。相反,它描述了项目规范所需的要素,并要求从业者在规范中说明省略任何要素的理由,此外,还要说明为每个要素提供的细节程度的理由。本文件是建模与模拟特别兴趣小组的一项倡议。建模与模拟特别兴趣小组是一个向制药行业统计学家协会成员和制药行业欧洲统计学家联合会开放的机构。附录中包含了非常详细的规范和不太详细的规范的示例。

相似文献

1
Proposed best practice for projects that involve modelling and simulation.针对涉及建模与仿真的项目所提议的最佳实践方法。
Pharm Stat. 2017 Mar;16(2):107-113. doi: 10.1002/pst.1789. Epub 2016 Nov 3.
2
Modelling and simulation in the pharmaceutical industry--some reflections.制药行业中的建模与模拟——一些思考
Pharm Stat. 2011 Nov-Dec;10(6):508-16. doi: 10.1002/pst.523. Epub 2011 Dec 8.
3
Analysis and Specification of Telemedical Systems Using Modelling and Simulation: the MOSAIK-M Approach.使用建模与仿真对远程医疗系统进行分析与规范:MOSAIK-M方法
Stud Health Technol Inform. 2005;116:503-8.
4
Modelling iterative compound optimisation using a self-avoiding walk.
Drug Discov Today. 2009 Feb;14(3-4):198-207. doi: 10.1016/j.drudis.2008.10.007. Epub 2008 Dec 8.
5
Modelling personal exposure to particulate air pollution: an assessment of time-integrated activity modelling, Monte Carlo simulation & artificial neural network approaches.
Int J Hyg Environ Health. 2015 Jan;218(1):107-16. doi: 10.1016/j.ijheh.2014.08.004. Epub 2014 Sep 16.
6
Quantitative risk modelling for new pharmaceutical compounds.新型药物化合物的定量风险建模
Drug Discov Today. 2005 Nov 15;10(22):1520-6. doi: 10.1016/S1359-6446(05)03606-8.
7
Calculation of out-of-field dose distribution in carbon-ion radiotherapy by Monte Carlo simulation.通过蒙特卡罗模拟计算碳离子放射治疗中的射野外剂量分布
Med Phys. 2012 Aug;39(8):5028-39. doi: 10.1118/1.4736823.
8
Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.系统生物学、生物标志物、生物模拟和建模在简化药物研发中的有效整合。
Eur J Pharm Sci. 2007 May;31(1):62-7. doi: 10.1016/j.ejps.2007.02.003. Epub 2007 Feb 20.
9
Monte Carlo reference data sets for imaging research: Executive summary of the report of AAPM Research Committee Task Group 195.用于成像研究的蒙特卡罗参考数据集:美国医学物理学家协会研究委员会任务组195报告执行摘要
Med Phys. 2015 Oct;42(10):5679-91. doi: 10.1118/1.4928676.
10
Clinical trial simulation in drug development.药物研发中的临床试验模拟
Pharm Res. 2000 Mar;17(3):252-6. doi: 10.1023/a:1007548719885.

引用本文的文献

1
Many nonnormalities, one simulation: Do different data generation algorithms affect study results?多种异常情况,一次模拟:不同的数据生成算法是否会影响研究结果?
Behav Res Methods. 2024 Oct;56(7):6464-6484. doi: 10.3758/s13428-024-02364-w. Epub 2024 Feb 22.
2
Using simulation studies to evaluate statistical methods.运用模拟研究评估统计方法。
Stat Med. 2019 May 20;38(11):2074-2102. doi: 10.1002/sim.8086. Epub 2019 Jan 16.
3
Model-Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives.
模型引导的药物发现和开发:当前行业良好实践和监管期望及未来展望。
CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):87-96. doi: 10.1002/psp4.12372. Epub 2019 Feb 1.
4
Model Description Language (MDL): A Standard for Modeling and Simulation.模型描述语言(MDL):建模与仿真的标准
CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):647-650. doi: 10.1002/psp4.12222. Epub 2017 Jul 12.